<DOC>
	<DOCNO>NCT01230645</DOCNO>
	<brief_summary>RV568 develop treatment disease asthma , COPD allergic rhinitis ( e.g . hayfever ) . The main aim study investigate whether RV568 effective reduce inflammation cause viral infection RSV ( respiratory syncytial virus ) .</brief_summary>
	<brief_title>RV568 - Viral Challenge With RSV</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>healthy male subject age 18 45 year agreeable use adequate contraception throughout study negative hepatitis B , hepatitis C HIV screen negative drug abuse , alcohol nicotine screen able provide write informed consent willing comply study restriction requirement low titre RSV neutralise antibody measure screen acute chronic illness clinically relevant abnormality note screen visit presence febrile illness symptom upper low respiratory tract infection 28 day prior viral inoculation history asthma , COPD , pulmonary hypertension , reactive airway disease , chronic lung condition diabetes history evidence autoimmune disease know impaired immune responsiveness recent ( within last 3 year ) and/or recurrent history autonomic dysfunction anatomic neurological abnormality impair gag reflex associate increase risk aspiration , abnormality significantly alter anatomy nose nasopharynx . Known IgA deficiency , immotile cilium syndrome , Kartagener 's syndrome . Any nasal sinus surgery within 4 month prior virus administration . history smoke past 6 month positive test drug alcohol screen inadequate venous access abnormal pulmonary function screen abnormal laboratory ECG screen acute chronic use medication treat nasal congestion use prescription drug , herbal supplement , within 4 week prior virus challenge , and/or overthecounter medication , dietary supplement within 2 week prior virus challenge treatment systemic glucocorticoid , antiviral drug , immunoglobulin blood transfusion within 1 month , cytotoxic immunosuppressive drug within 6 month prior dose . Receipt systemic chemotherapy agent time treatment investigational drug within 3 month , prior participation clinical trial RSV IMP , medication experimental RSV viral challenge deliver directly respiratory tract within 1 year prior dosing , receipt 4 investigational drug within 12 month history multiple recur allergy and/or adverse reaction component challenge virus preparation allergy gentamicin significant history seasonal hay fever seasonal allergic rhinitis ( SAR ) , perennial allergic rhinitis ( PAR ) , chronic nasal sinus condition intention travel first last visit ( country vaccination recommend high risk infection exists ) healthcare worker ( include doctor , nurse , medical student ally healthcare professional ) anticipate patient contact within two week viral challenge household member close contact ( additional 2 week discharge isolation facility ) : 1. less 3 year age ; 2. person know immunodeficiency ; 3. person receive immunosuppressant medication ; 4. person undergo soon undergo cancer chemotherapy within 28 day viral challenge ; 5. person diagnose emphysema COPD , elderly reside nursing home , severe lung disease medical condition include exclusive condition list ; 6. person receive transplant ( bone marrow solid organ ) employee relatives Retroscreen Virology RespiVert Ltd find medical interview , physical exam , screen investigation , opinion Investigator , deem subject unsuitable study subject opinion general practitioner Investigator , participate study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>